Chemical Pathology Department, Southampton University Hospital NHS Trust, Southampton SO16 6YD, UK.
Drug Discov Today. 2010 Aug;15(15-16):590-5. doi: 10.1016/j.drudis.2010.06.007. Epub 2010 Jun 18.
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with marked insulin resistance and increased risk of cardiovascular disease. Ezetimibe, an inhibitor of intestinal cholesterol absorption, inhibits Niemann-Pick C1-like 1 (NPC1L1). Interestingly, NPC1L1 is abundantly expressed in human liver, as well as in the intestine. Recent reports suggest a potential benefit of ezetimibe in improving hepatic insulin sensitivity and decreasing hepatic inflammation and lipid accumulation. Insulin resistance and excess hepatic fat accumulation are regarded as key factors in the pathogenesis of NAFLD. We suggest, therefore, that urgent studies are needed to assess the potential therapeutic benefit of ezetimibe in treating NAFLD.
非酒精性脂肪性肝病（NAFLD）是代谢综合征的肝脏组成部分，已知与明显的胰岛素抵抗和心血管疾病风险增加有关。依泽替米贝，一种肠内胆固醇吸收抑制剂，可抑制尼曼-匹克 C1 样 1（NPC1L1）。有趣的是，NPC1L1 在人类肝脏以及肠道中大量表达。最近的报告表明，依泽替米贝在改善肝脏胰岛素敏感性、减少肝脏炎症和脂质积聚方面可能具有潜在益处。胰岛素抵抗和肝脏脂肪过度堆积被认为是 NAFLD 发病机制中的关键因素。因此，我们建议迫切需要进行研究来评估依泽替米贝在治疗 NAFLD 方面的潜在治疗益处。
